WASHINGTON — An advisory panel has urged the Food and Drug Administration to loosen its restrictions on the controversial diabetes drug Avandia, which was nearly wiped from the market in recent years after reports linking it to several heart-related complications.Read More »
GlaxoSmithKline has agreed to plead guilty and pay $3 billion to resolve charges that the pharmaceutical giant fraudulently marketed the prescription drugs Paxil, Wellbutrin and Avandia, the U.S. Justice Department has announced.Read More »
The anti-nausea drug Reglan and its generic counterparts were the drugs most frequently cited in litigation in 2011, according to a consumer watchdog’s latest analysis of Food and Drug Administration statistics.
Tagged with: Accutane adverse events Avandia Bayer Chantix Coumadin drug litigation FDA Food and Drug Administration GlaxoSmithKline Hoffman-LaRoche Institute for Safe Medication Practices Johnson & Johnson Levaquin Pfizer Pradaxa prescription drugs Reglan Wyeth Yasmin YazRead More »
GlaxoSmithKline has announced a tentative deal with the federal government under which the drug company would pay a record $3 billion to end an investigation into the marketing of Avandia for “off-label” uses.Read More »
Recently filed product liability claims relating to the diabetes drug Avandia are not time-barred, even though the drug maker contended that the risks were widely known back in 2007, a U.S. District Court in Pennsylvania has ruled in denying a ...Read More »
WASHINGTON – The Food and Drug Administration has set new restrictions on the distribution and use of controversial diabetes drugs Avandia, Avandamet and Avandaryl, which have been linked to a higher risk of heart attacks.Read More »